NEWARK, Calif., Jan. 4, 2021 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will present at the 39th Annual J.P. Morgan
Healthcare Conference on Monday, January 11,
2021, at 2:00 p.m EST.
A live and archived webcast of the event will be available in
the Investors section of the Protagonist Therapeutics website at
https://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company with multiple peptide-based new chemical entities in
different stages of development. PTG-300 is an injectable hepcidin
mimetic in a Phase 2 proof-of-concept clinical trial for
polycythemia vera, and a separate Phase 2 clinical study for
hereditary hemochromatosis. PTG-200 is an orally delivered,
gut-restricted, interleukin-23 receptor specific antagonist peptide
in a Phase 2 clinical trial for Crohn's disease. Two additional
oral peptide interleukin-23 receptor antagonist candidates are in
development: PN-235, in a Phase 1 study, and PN-232, in the late
preclinical stage. PN-943 is an orally delivered, gut-restricted
alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2
study for the potential treatment of inflammatory bowel disease,
with ulcerative colitis as the initial targeted indication. The
Company utilizes a proprietary technology platform to discover and
develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms.
Protagonist is headquartered in Newark, California. For further information,
please visit www.protagonist-inc.com.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301199869.html
SOURCE Protagonist Therapeutics, Inc.